[PRESSWIRE] DUBLIN, May 23, 2017 -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced that Emmy®and Tony® award-winning actress and singer, Kristin Chenoweth will kick off the "Less Red, More You" campaign today at an exclusive event in New York City.
Press Releases in Pharmaceuticals
[PRESSWIRE] BRUSSELS, May 16, 2017 -- Systech International, a global technology solutions leader for the pharmaceutical industry, is proud to announce its upcoming serialisation webinar titled "The Clock is Ticking: Overcoming the Challenges of Implementing Serialisation in the EU"on 24 May 2017.
[PRESSWIRE] Calgary, Alberta, Canada - 27 March, 2017 -- Developed by AOR, Curcumin Ultra combines superior free-form curcumin (CurQfen®) with water-soluble turmeric polysaccharides (Turmacin®) for a long lasting synergistic effect for inflammation and pain relief.
[PRESSWIRE] SYDNEY, March 6, 2017 --Australian oncology-focused biotechnology company Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to announce that it has been awarded a grant of up to A$3m over three years under the Cooperative Research Centre Project (CRC-P) scheme managed by the Australian Department of Industry Innovation and Science (DIIS).
[PRESSWIRE] WESTERHAM, England, January 16, 2017 -- A major investment in the leading source of drug discovery industry information - Drug Target Review - has led to a comprehensive relaunch.
[PRESSWIRE] INDIANAPOLIS, January 5, 2017 -- Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities.
[PRESSWIRE] BENGALURU, October 19, 2016 -- Jubilant Biosys is proud to announce the addition of Agilent Technologies' RapidFire/MS screening technology to its Integrated Drug Discovery Platform.
[PRESSWIRE] LONG BEACH, Calif. - 10 October, 2016 -- SCAN Health Plan announced today its 2017 benefit plans, which include a new Preferred Pharmacy program offering lower copayments for prescription drugs. In many counties this gives plan members the option to pay $0 for many commonly used generic drugs.
[PRESSWIRE] CHARLOTTESVILLE, Va. - 26 September, 2016 -- Cavion LLC, a pharmaceutical company developing T-type calcium channel (Cav3) inhibitors for the treatment of oncologic and neurologic diseases, announced today that Ranjit Bindra, MD, PhD and Nataniel Lester-Coll, MD will present preliminary results from an ongoing Yale University Cancer Center and Cavion-sponsored Phase 1 clinical trial at the Annual Meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO) being held in Boston, Massachusetts, September 25-28.